Early-dose trial of BP1001-A for advanced or recurrent solid tumors
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older with an advanced or recurring solid tumor that has no other standard treatment likely to help
- Be in good enough shape for treatment (performance status 0 or 1)
- Be willing to get a biopsy before starting, and possibly another biopsy after 1 treatment cycle
- Have tumors that can be measured on scans (at least one measurable “target” spot) and that can be biopsied
- Have test results showing enough blood, liver, kidney, and clotting function for treatment
- Not be pregnant or breastfeeding; and agree to use effective birth control during the study and for at least 6 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests BL-B01D1 in people with recurrent or metastatic gynecologic cancers (such as ovarian, uterine, or cervical cancer) when standard treatments have failed or aren’t options. It focuses on how well the drug works and whether it can be given safely.
This trial tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if PHST001 can help shrink or control the tumor.
This study tests whether adding weekly paclitaxel to an experimental drug called OK-1 can help treat advanced or recurrent endometrial cancer that has stopped responding to other treatments. It aims to see if the combination is safe and effective.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This trial tests a new drug called BMX-001 combined with the chemotherapy drug paclitaxel for people with advanced ovarian or endometrial cancer that has come back or spread. The goal is to see if this combination can help control the cancer.
This trial tests a new drug called ASP1002, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if ASP1002 can shrink tumors or slow their growth.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.